SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

BIOHARVEST SCIENCES INC.
Date: Sept. 3, 2025 · CIK: 0001723464 · Accession: 0000000000-25-009482

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-289908

Date
September 3, 2025
Author
Division of
Form
UPLOAD
Company
BIOHARVEST SCIENCES INC.

Letter

Re: BioHarvest Sciences Inc. Registration Statement on Form F-3 Filed August 28, 2025 File No. 333-289908 Dear Ilan Sobel:

September 3, 2025

Ilan Sobel Chief Executive Officer BioHarvest Sciences Inc. 1140-625 Howe Street Vancouver, British Columbia V6C 2T6, Canada

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tim Buchmiller at 202-551-3635 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Stephen F.X. O Neill, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 September 3, 2025

Ilan Sobel
Chief Executive Officer
BioHarvest Sciences Inc.
1140-625 Howe Street
Vancouver, British Columbia
V6C 2T6, Canada

 Re: BioHarvest Sciences Inc.
 Registration Statement on Form F-3
 Filed August 28, 2025
 File No. 333-289908
Dear Ilan Sobel:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Tim Buchmiller at 202-551-3635 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Stephen F.X. O Neill, Esq.
</TEXT>
</DOCUMENT>